Investment
Features
FeesSafety
Academy
More
Pluang+

Jio Platforms' IPO anchor book oversubscribed 30x with $26.3B bids from top global investors

Market News
19 Oct 2026
CNBC
View Source
Bullish
Jio Platforms' IPO anchor book oversubscribed 30x with $26.3B bids from top global investors

Jio Platforms, backed by Meta and Google, has seen its IPO anchor book oversubscribed over 30 times, attracting $26.3 billion in bids for an $854 million portion. The company aims to raise up to $3.2 billion in India's largest-ever IPO by rupee value, valuing Jio at around $108 billion. Major institutional investors including BlackRock, Capital Group, and India's Life Insurance Corporation have secured shares. The public IPO opens Wednesday through Friday, marking a significant step as Jio positions itself as a tech company beyond traditional telecom services.

Jio Platforms' IPO has attracted significant investor interest, with anchor bids topping $26 billion. For readers following the broader technology sector, here is Pluang's market snapshot as of Oct 20, 2026 10:01 WIB: out of 150 priced US technology stocks, 118 rose and 28 fell today. Notable movers include Twilio Inc (TWLO) at USD 257.29 with a 5.29% increase and 100% buy order activity, Western Digital Corp (WDC) at USD 349.06 with a 5.14% increase and a 55% buy order activity, and Palantir Technologies Inc (PLTR) at USD 194.77 with a 4.70% increase and a 54% buy order activity.

More News

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...

Market News
Bullish
1 hour ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
4 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
4 hours ago
Solana's non-vote transactions hit 8.92B in Q3 2026, up 104% from Q4 2025, setting new weekly and monthly records.

Solana's non-vote transactions hit 8.92B in Q3 2026, up 104% from Q4 2025, setting new weekly and monthly records.

Solana recorded 8.92 billion non-vote transactions from July to September 2026, marking a 104% increase compared to the fourth quarter of 2025. These transactions exclude validator votes and include activities like transfers, trading, and decentraliz...

Protocol Fundamentals
Bullish
4 hours ago
Brave introduces AI agent payments with stablecoins and expands BAT rewards in new roadmap.

Brave introduces AI agent payments with stablecoins and expands BAT rewards in new roadmap.

Brave has launched a payment system allowing AI agents to pay for individual Search API requests using stablecoins, without needing accounts or API keys. The company's BAT Roadmap 4.0 outlines plans to expand payment support across Brave products, in...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App